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Background: Anti-parathyroid treatment initiation and discontinuation are important deci-
sions  in chronic haemodialysis (HD) patients, where pill burden is often excessive. The
present study aimed to describe secondary hyperparathyroidism (sHPT) drug therapy
changes in HD patients.
Methods: Retrospective observational cohort study of incident European HD patients with
sHPT who were prescribed calcitriol or alfacalcidol (alpha calcitriol), paricalcitol or cinacal-
cet.
Results: Treatment-naïve patients prescribed alpha calcitriol (N = 2259), paricalcitol (N = 1689)
and cinacalcet (N = 1245) were considered for analysis. Serum intact parathyroid hormone
(iPTH) levels decreased post-initiation with all treatment modalities; serum calcium and
phosphate levels increased in response to activated vitamin D derivatives but decreasedroximately one-third of alpha calcitriol and paricalcitol patients butTreatment initiation with cinacalcet. AppTreatment persistence
Treatment discontinuation
less  than one-quarter of cinacalcet patients discontinued treatment. Although the three
groups had comparable serum iPTH control at the time of treatment discontinuation, they
differed in terms of calcium and phosphate levels. Following discontinuation, the evolution
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differed by treatment modality: whilst iPTH increased for all three treatment groups, cal-
cium  and phosphate decreased in patients who were being treated with alpha calcitriol and
paricalcitol at the time of discontinuation, and increased in those who had been treated
with cinacalcet.
Conclusions: In conditions of daily clinical practice, attaining and maintaining recommended
biochemical control of sHPT appears to be more frequently achievable with cinacalcet than
with  activated vitamin D compounds.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Efectividad  y  persistencia  de  los  tratamientos  del  hiperparatiroidismo
secundario  en  pacientes  incidentes  en  hemodialisis
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r  e  s  u  m  e  n
Antecedentes: El inicio y la discontinuación del tratamiento antiparatiroideo son decisiones
importantes en los pacientes en hemodiálisis crónica (HD) en los que la carga de pastil-
las  es con frecuencia excesiva. El objetivo de este estudio es describir de tratamiento del
hiperparatiroidismo secundario (sHPT) en pacientes en HD.
Métodos: Estudio de cohorte, observacional retrospectivo de pacientes europeos incidentes
en  HD con sHPT a quienes se prescribió calcitriol o alfacalcidol (calcitriol-alfa), paricalcitol
o  cinacalcet.
Resultados: Se incluyeron en el análisis pacientes que recibieron por primera vez calcitriol-
alfa (N = 2259), paricalcitol (N = 1689) y cinacalcet (N = 1245). Los valores sericos de hormona
paratiroidea intacta (iPTH) disminuyeron tras iniciación con todos los tratamientos; los val-
ores de calcio y fosforo serico se elevaron en respuesta al tratamiento con activadores de
vitamina D pero disminuyeron con cinacalcet. Aproximadamente un tercio de los pacientes
que  recibieron calcitriol alfa y paricalcitol, y menos de una cuarta parte de los de cinacalcet
discontinuaron el tratamiento. Aunque los tres grupos tuvieron descensos comparables de
iPTH al momento de la interrupción del tratamiento, sin embargo diﬁrieron en los valores
de  calcio y fosforo serico. Tras la interrupción, la evolución de los parámetros de laboratorio
fué  diferente según la modalidad de tratamiento: mientras que la iPTH se elevó en las tres
modalidades, el calcio y fosforo sericos disminuyeron en los pacientes que estaban siendo
tratados con calcitriol-alfa y paricalcitol en el momento de la interrupción y aumentaron
en  los que lo hacían con cinacalcet.
Conclusiones: En condiciones clínicas que representan la practica diaria, alcanzar y mantener
los valores recomendados para el control del sHPT se consigue más  frecuentemente con
cinacalcet que con compuestos activos de vitamina D.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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econdary hyperparathyroidism (sHPT) occurs early in chronic
idney disease (CKD) and is a major component of the CKD-
elated mineral and bone disorder (CKD-MBD).1 Major CKD-
BD  complications include fractures, cardiovascular disease
CVD), and mortality.2–7
Control of serum calcium, phosphorus and PTH has been
ssociated with reduced mortality risk in haemodialysis
atients,8 hence effective sHPT control is important in these
atients. Reduced persistence, compliance, and/or adherence
ith oral medications are a common problem, especially
n CKD patients,9 with non-adherence rates of 3–80%
eported.10–12 Non-adherence was associated with increased(http://creativecommons.org/licenses/by-nc-nd/4.0/).
mortality in the dialysis population,13 highlighting a potential
unmet need among patients who do not persist with sHPT
therapies. Clinical trial data,14 where persistence-corrected
analyses revealed more  beneﬁcial effects associated with
cinacalcet (Sensipar®/Mimpara®) prescribing than uncor-
rected analyses, support this hypothesis.
The current study, conducted in European patients ini-
tiating haemodialysis (HD) treatment, aimed to describe
separately the characteristics of patients who initiated long-
term sHPT therapies with either prescribed activated vitamin
D sterols (AVDs) or cinacalcet, the conditions and reasons
for non-persistence and the consequences of initiation and
non-persistence, respectively, for the control of serum bio-
chemistry parameters.
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Methods
Data  source
A retrospective cohort study was conducted using the sec-
ond cohort of the Analysing Data, Recognising Excellence
and Optimising Outcomes research initiative (AROii).15,16
Anonymised patient-level medical history data, longitudinal
laboratory, dialysis and medication data, plus ICD-10 coded
hospitalisation and death data17 are supplied quarterly. All
ethical and regulatory obligations concerning patient data
in this study were met  locally and informed consent was
obtained from all patients.
Study  population
The study population included incident (<183 days dialysis
vintage, i.e. the time since dialysis initiation) adult patients
(≥18 years) receiving haemodialysis at >300 Fresenius Medical
Care (EU-FMC) facilities in 14 European countries and Turkey
from 2007 to 2009.16 Patients on short-term haemodialysis
treatment (<10 contiguous dialysis sessions), with a history of
peritoneal dialysis or kidney transplantation were excluded.
Patients with <90 days of follow-up or a parathyroidectomy
history of up to/including the ﬁrst 90 days of follow-up were
also excluded.
Patients’ ﬁrst haemodialysis session deﬁned study start
and follow-up start. Three sub-populations, compris-
ing patients prescribed calcitriol/alfacalcidol (henceforth
calcitriol-alfa), paricalcitol or cinacalcet, were created. Within
each treatment sub-population, patients were excluded if
HD
No treatment
Init
90d BL
Abbreviations:
HD, Hemodialysis;
Init, Initiation;
NP, Non-persistence;
BL, Baseline;
Fig. 1 – Study schema summarising baseline and trajectory perio
treatment.3  6(2):164–175
they were prescribed that treatment before study start or
during the ﬁrst 90 days of follow-up (to exclude prevalent
users), if the ﬁrst prescription duration was less than 15 days
with no further treatment prescriptions (to effectively capture
therapeutic effects) or if the ﬁrst AVDs and cinacalcet pre-
scriptions were on the same day (to distinguish the therapy
effects).
Initiation,  discontinuation  deﬁnitions
Initiation was deﬁned by patients’ ﬁrst prescription start
date for each treatment (henceforth initiation index date;
Fig. 1). If patients’ ﬁrst prescription was <15 days long and
the gap between prescription end and the next was  >15
days then the next prescription was considered for initia-
tion (with the same rules applied) and so forth. Treatment
discontinuation was deﬁned as the time point (henceforth
discontinuation index date) beyond which there were ≥45
consecutive prescription-free days. Patients were considered
persistent until discontinuation.
The 90 days before each index date constituted
baseline. Patients were followed-up for 12 months post-
initiation/discontinuation or until end of follow-up (ﬁrst
occurrence of parathyroidectomy, renal transplantation,
death or loss-to-follow-up (>45 days without EU-FMC dialysis)
or end of study follow-up (31 December 2013)).
Serum  biochemistrySerum concentrations of total calcium (henceforth calcium),
phosphate and parathyroid hormone (PTH) were measured
locally. Serum ‘intact’ PTH (iPTH) values were determined
Subset
initiating
Subset
discontinuing
NP
90d BL
Persistence
Trajectory
Non-persitence
Trajectory
ds for patients initiating and discontinuing CKD-MBD
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AROii patients
(countries with cinacalet
access; n=10,646)
Remaining Patients
(n=9597)
Calcitriol-alfa
(n=5455; 56.8%)
Therapy exclusion (3196; 58.6%):
Therapy use  up 1st 90 days of
follow-up (3134; 57.5)
First prescription <15 days 
and no further use (111; 2.0)
Multiple therapy start (40; 0.7%)
Therapy exclusion (1019; 37.6%) :
Cinacalcet
(n=1245)
Paricalcitol
(n=1689)
Calcitriol-alfa
(n=2259)
Therapy use  up 1st 90 days of
follow-up (972; 35.9%)
First prescription <15 days and 
no further use (52; 1.9)
Multiple therapy start (34; 1.3%)
Therapy exclusion (319; 20.4%):
Therapy use  up 1st 90 days of
follow-up (268; 17.1%)
First prescription <15 days and 
no further use (35; 2.2)
Multiple therapy start (74; 4.7%)
Paricalcitol
(n=2708; 28.2%) Cinacalcet(n=1564; 16.v3%)
General exclusion (1049; 9.9%):
<3 months follow-up (1037; 9.7%)
Baseline PTX history (13; 0.1%)
•
•
•
•
•
•
•
•
•
Fig. 2 – Selection of the study population.
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tocally with different assays. Uncorrected iPTH concentrations
ere used.
tatistical  analysis
tatistical analyses were conducted in SAS (version 9.2; SAS,
ary, NC, USA) and reproduced independently. Initially, base-
ine characteristics of initiating and discontinuing patients
ere presented. Data were categorised into quartiles or bio-
ogically relevant groups. Continuous variables were described
sing mean, standard deviation, median, 25th and 75th per-
entile values; categorical data were reported as counts and
ercentages.
Mean calcium, phosphate and iPTH values were deter-
ined at baseline and each quarter during the 12 months
ost-initiation/discontinuation or end of follow-up (whichever
ccurred ﬁrst), with the average change from baseline also
resented. Median percentage change from baseline was pre-
ented to reﬂect the skewed distribution of these values.
To describe treatment persistence patterns, Kaplan–Meier
stimates for time-to-discontinuation were computed and
raphically displayed. Quarterly post-initiation Kaplan–Meier
ersistence probabilities were estimated with 95% conﬁdence
ntervals (CI).ensitivity/additional  analyses
 sensitivity discontinuation deﬁnition was applied to inves-
igate its effect on the ﬁndings: discontinuation was deﬁnedas the start of the 90-day interval post-initiation where the
proportion of prescribed days over the interval was <67% (i.e.
<60/90 days coverage).
Results
Study  population
Between 01 January 2007 and 31 December 2009, 10,646 chronic
haemodialysis patients treated in 310 EU-FMC facilities in 14
European countries and in Turkey were recruited (Fig. 2). Of
these, 1049 patients (9.9%) were excluded because their follow-
up was <90 days (1037; 9.7%) or for a parathyroidectomy history
(13; 0.1%), leaving 9597 patients for the treatment-speciﬁc
analyses.
Prescribed drugs for sHPT treatment were calcitriol-alfa
(5455 patients; 56.8%); paricalcitol (2708 patients; 28.2%); and
cinacalcet (1564; 16.3%). Among these, 57.5%, 35.9% and
17.1%, respectively, were prescribed treatments in the ﬁrst
90 days of HD; most treated patients were excluded for this
reason. Additionally, cinacalcet patients were more  often
excluded due to multiple therapy starts. Applying all the
exclusion criteria, 2259 calcitriol-alfa, 1689 paricalcitol and
1245 cinacalcet patients remained. Most initial paricalcitol
prescriptions (1459; 86.4%) were administered intravenously;
calcitriol-alfa and cinacalcet are oral medications. Most
cinacalcet patients (996; 80.0%) had previously initiated
AVD.
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Table 1 – Characteristics of patients in the 90 days prior to initiating and discontinuing CKD-MBD treatment.
Parameter Initiation Discontinuation
Calcitriol-alfaa Paricalcitol Cinacalcet Calcitriol-alfa Paricalcitol Cinacalcet
(N = 2259) (N = 1689) (N = 1245) (N = 755) (N = 540) (N = 290)
Age
Mean ± SD 64.3 ± 14.5 65.2 ± 14.8 63.4 ± 15.4 63.3 ± 14.3 64.2 ± 14.8 65.3 ± 15.1
Gender
Male 1304 (57.7) 1026 (60.7) 709 (56.9) 416 (55.1) 325 (60.2) 158 (54.5)
Female 955 (42.3) 663 (39.3) 536 (43.1) 339 (44.9) 215 (39.8) 132 (45.5)
Geographical area
Eastern Europed 950 (42.1) 436 (25.8) 121 (9.7) 450 (59.6) 181 (33.5) 19 (6.6)
Western Europee 479 (21.2) 130 (7.7) 130 (10.4) 76 (10.1) 34 (6.3) 22 (7.6)
Iberian peninsulaf 830 (36.7) 1123 (66.5) 994 (79.8) 229 (30.3) 325 (60.2) 249 (85.9)
Period pre-KDIGOb
Yes 743 (32.9) 503 (29.8) 276 (22.2) 170 (22.5) 96 (17.8) 44 (15.2)
No 1516 (67.1) 1186 (70.2) 969 (77.8) 585 (77.5) 444 (82.2) 246 (84.8)
Smoking status
Current 179 (7.9) 167 (9.9) 131 (10.5) 64 (8.5) 59 (10.9) 27 (9.3)
Former 356 (15.8) 293 (17.3) 164 (13.2) 131 (17.4) 95 (17.6) 36 (12.4)
Non-smoker 1016 (45.0) 634 (37.5) 423 (34.0) 380 (50.3) 240 (44.4) 102 (35.2)
Missing 708 (31.3) 595 (35.2) 527 (42.3) 180 (23.8) 146 (27.0) 125 (43.1)
BMI (kg/m2)
<18.5 70 (3.1) 37 (2.2) 23 (1.8) 21 (2.8) 12 (2.2) 5 (1.7)
18.5–<25 795 (35.2) 596 (35.3) 404 (32.4) 259 (34.3) 188 (34.8) 86 (29.7)
25–<30 677 (30.0) 554 (32.8) 438 (35.2) 240 (31.8) 187 (34.6) 107 (36.9)
≥30 440 (19.5) 340 (20.1) 252 (20.2) 161 (21.3) 100 (18.5) 64 (22.1)
Missing 277 (12.3) 162 (9.6) 128 (10.3) 74 (9.8) 53 (9.8) 28 (9.7)
Blood pressure (mmHg)c
<120 435 (19.3) 374 (22.1) 209 (16.8) 156 (20.7) 136 (25.2) 78 (26.9)
120–<130 459 (20.3) 360 (21.3) 237 (19.0) 142 (18.8) 104 (19.3) 44 (15.2)
130–<140 483 (21.4) 337 (20.0) 266 (21.4) 170 (22.5) 122 (22.6) 67 (23.1)
140–<160 677 (30.0) 473 (28.0) 409 (32.9) 216 (28.6) 144 (26.7) 78 (26.9)
≥160 205 (9.1) 145 (8.6) 124 (10.0) 71 (9.4) 34 (6.3) 23 (7.9)
Clinical history
Hospitalisation 312 (13.8) 206 (12.2) 121 (9.7) 92 (12.2) 71 (13.1) 31 (10.7)
Diabetes 809 (35.8) 598 (35.4) 385 (30.9) 266 (35.2) 176 (32.6) 89 (30.7)
Cancer 154 (6.8) 131 (7.8) 116 (9.3) 47 (6.2) 46 (8.5) 35 (12.1)
Cardiovascular disease 812 (35.9) 740 (43.8) 569 (45.7) 271 (35.9) 238 (44.1) 151 (52.1)
Fracture 52 (2.3) 61 (3.6) 59 (4.7) 24 (3.2) 17 (3.1) 19 (6.6)
CKD aetiology
Hypertension/vascular 373 (16.5) 319 (18.9) 216 (17.3) 144 (19.1) 98 (18.1) 56 (19.3)
Glomerulonephritis 214 (9.5) 156 (9.2) 154 (12.4) 72 (9.5) 47 (8.7) 36 (12.4)
Diabetes 516 (22.8) 400 (23.7) 235 (18.9) 174 (23.0) 106 (19.6) 61 (21.0)
Tubulo-interstitial 228 (10.1) 158 (9.4) 145 (11.6) 82 (10.9) 52 (9.6) 31 (10.7)
Polycystic kidney disease 114 (5.0) 107 (6.3) 88 (7.1) 44 (5.8) 36 (6.7) 19 (6.6)
Invalid/missing/unknown 814 (36.0) 549 (32.5) 407 (32.7) 239 (31.7) 201 (37.2) 87 (30.0)
Dialysis vintage (days)
Mean ± SD 575.8 ± 434.1 664.1 ± 477.0 758.8 ± 490.3 701.5 ± 401.4 800.4 ± 432.8 885.8 ± 449.5
Dialysate calcium concentration (mEq/L)
Mean ± SD 2.871 ± 0.289 2.825 ± 0.251 2.760 ± 0.255 2.909 ± 0.295 2.820 ± 0.258 2.832 ± 0.258
<3.0 722 (32.0) 670 (39.7) 631 (50.7) 232 (30.7) 233 (43.1) 116 (40.0)
≥3.0 1316 (58.3) 962 (57.0) 563 (45.2) 476 (63.0) 294 (54.4) 168 (57.9)
Missing 221 (9.8) 57 (3.4) 51 (4.1) 47 (6.2) 13 (2.4) 6 (2.1)
Catheter vascular access
Yes 587 (26.0) 477 (28.2) 324 (26.0) 149 (19.7) 125 (23.1) 77 (26.6)
No 1511 (66.9) 1135 (67.2) 878 (70.5) 558 (73.9) 391 (72.4) 206 (71.0)
Missing 161 (7.1) 77 (4.6) 43 (3.5) 48 (6.4) 24 (4.4) 7 (2.4)
Net ultraﬁltration (L)
Mean ± SD 1.97 ± 0.83 2.07 ± 0.80 2.05 ± 0.78 2.03 ± 0.85 2.09 ± 0.84 2.03 ± 0.79
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Table 1 – (Continued)
Parameter Initiation Discontinuation
Calcitriol-alfaa Paricalcitol Cinacalcet Calcitriol-alfa Paricalcitol Cinacalcet
(N = 2259) (N = 1689) (N = 1245) (N = 755) (N = 540) (N = 290)
Laboratory parametersg
Blood hemoglobin (g/dL) 11.51 ± 1.39 11.77 ± 1.38 11.87 ± 1.31 11.48 ± 1.35 11.81 ± 1.37 11.59 ± 1.46
Ferritin (g/L) 479.8 ± 286.8 469.6 ± 291.9 441.0 ± 267.9 530.6 ± 293.4 502.6 ± 295.7 455.6 ± 266.2
Serum CRP (mg/L)h 5.3 [2.1,13.6] 5.4 [2.0,13.3] 4.9 [1.9,10.5] 5.4 [2.2,12.5] 5 [1.6,14.1] 4.9 [2.0,11.2]
Serum albumin (g/L) 38.6 ± 4.7 39.1 ± 4.4 39.7 ± 4.4 39.6 ± 4.3 39.6 ± 3.8 38.9 ± 4.6
Serum creatinine (mol/L) 661.5 ± 213.0 664.6 ± 196.3 728.7 ± 207.5 697.7 ± 211.5 691.3 ± 184.7 706.8 ± 203.2
Serum total calcium (mmol/L) 2.17 ± 0.19 2.17 ± 0.17 2.28 ± 0.19 2.26 ± 0.21 2.33 ± 0.22 2.14 ± 0.21
Serum phosphate (mmol/L) 1.45 ± 0.43 1.48 ± 0.40 1.73 ± 0.48 1.65 ± 0.51 1.66 ± 0.52 1.45 ± 0.47
Serum iPTH (pg/mL) 419.3 ± 336.7 499.8 ± 287.1 663.4 ± 371.4 296.4 ± 295 276.4 ± 285 313.1 ± 387.7
Serum calcium (mmol/L)
<2.10 708 (31.3) 491 (29.1) 180 (14.5) 131 (17.4) 57 (10.6) 112 (38.6)
≥2.10–≤2.37 1219 (54.0) 989 (58.6) 674 (54.1) 421 (55.8) 280 (51.9) 133 (45.9)
>2.37 261 (11.6) 192 (11.4) 376 (30.2) 199 (26.4) 200 (37.0) 42 (14.5)
Missing 71 (3.1) 17 (1.0) 15 (1.2) 4 (0.5) 3 (0.6) 3 (1.0)
Serum phosphate (mmol/L)
<1.13 475 (21.0) 272 (16.1) 102 (8.2) 120 (15.9) 80 (14.8) 63 (21.7)
≥1.13–≤1.78 1345 (59.5) 1113 (65.9) 626 (50.3) 343 (45.4) 248 (45.9) 167 (57.6)
>1.78 419 (18.5) 292 (17.3) 512 (41.1) 292 (38.7) 211 (39.1) 59 (20.3)
Missing 20 (0.9) 12 (0.7) 5 (0.4) 0 (0.0) 1 (0.2) 1 (0.3)
Serum iPTH (pg/mL)
<150 225 (10.0) 77 (4.6) 40 (3.2) 263 (34.8) 215 (39.8) 133 (45.9)
≥150–<300 462 (20.5) 246 (14.6) 65 (5.2) 174 (23.0) 139 (25.7) 69 (23.8)
≥300–<600 882 (39.0) 855 (50.6) 502 (40.3) 145 (19.2) 127 (23.5) 41 (14.1)
≥600 302 (13.4) 414 (24.5) 562 (45.1) 87 (11.5) 49 (9.1) 44 (15.2)
Missing 388 (17.2) 97 (5.7) 76 (6.1) 86 (11.4) 10 (1.9) 3 (1.0)
Concomitant medication
Calcitriol/alfacalcidol – 613 (36.3) 345 (27.7) – 84 (15.6) 72 (24.8)
Paricalcitol 177 (7.8) – 500 (40.2) 17 (2.3) – 124 (42.8)
Cinacalcet 136 (6.0) 231 (13.7) – 37 (4.9) 117 (21.7) –
Cardiovascular medicationi 1451 (64.2) 1277 (75.6) 1004 (80.6) 505 (66.9) 415 (76.9) 237 (81.7)
Phosphate binder use
None 1107 (49.0) 503 (29.8) 296 (23.8) 266 (35.2) 106 (19.6) 59 (20.3)
Calcium-based 872 (38.6) 727 (43.0) 433 (34.8) 405 (53.6) 243 (45.0) 126 (43.4)
Non calcium-based 280 (12.4) 459 (27.2) 516 (41.4) 84 (11.1) 191 (35.4) 105 (36.2)
NB, all data are n (%) unless stated otherwise.
a Calcitriol/alfacalcidol.
b Kidney Disease: Improving Global Outcomes CKD-MBD Work Group publication (01 August 2009).
c Pre-dialysis systolic.
d Czech Republic, Hungary, Poland, Romania, Russia, Serbia, Slovak Republic, Slovenia and Turkey.
e France, Ireland, Italy and United Kingdom.
f Portugal and Spain.
g Mean ± standard deviation unless stated otherwise.
h Median [Q1,Q3].
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atient  characteristics  by  treatment  type
aseline  characteristics  at  initiation
arge geographical differences were observed in patients ini-
iating calcitriol-alfa, paricalcitol and cinacalcet treatment
Table 1), probably related to differing drug access and
eimbursement policies. Similarly, the decreasing trend for
nitiating treatment after the KDIGO guideline2 publication
ay reﬂect differing marketing authorisation (calcitriol-alfa,
hen paricalcitol, then cinacalcet). No major clinical history
ifferences were apparent.ular).
Cinacalcet patients’ dialysis vintage exceeded paricalci-
tol patients’ vintage, which in turn exceeded calcitriol-alfa
patients’. Lower dialysate calcium concentrations (<3.0 mEq/L)
were utilised for paricalcitol or calcitriol-alfa initiators than for
cinacalcet initiators; other dialysis parameters were compara-
ble.
The initial extent of CKD-MBD, based on mean serum
biochemistry, showed higher levels of calcium (2.28 [95%
CI: 2.27,2.29] mmol/L), phosphate (1.73 [95% CI: 1.71,1.76]
mmol/L) and iPTH (663 [95% CI: 642,685] pg/mL) for cinacalcet
patients when compared to paricalcitol (calcium 2.17 [95% CI:
 0 1 6;170  n e f r o l o g i a 2
2.16,2.18] mmol/L, phosphate 1.48 [95% CI: 1.46,1.50] mmol/L
and iPTH 500 [95% CI: 486,514] pg/mL) and calcitriol-alfa (cal-
cium 2.17 [95% CI: 2.16,2.17] mmol/L, phosphate 1.45 [95%
CI: 1.43,1.47] mmol/L and iPTH 419 [95% CI: 404,435] pg/mL)
patients, respectively. No clinical differences between parical-
citol and calcitriol-alfa were observed with regard to serum
biochemistry-based CKD-MBD severity.
For baseline concomitant therapies, calcitriol-alfa patients
were prescribed phosphate binders less frequently; com-
pared with calcitriol-alfa patients, the proportion of patients
prescribed non-calcium-based phosphate binders was more
than double for paricalcitol patients and nearly fourfold
higher for cinacalcet patients. Cinacalcet patients were
often prescribed concomitant AVDs. Cardiovascular medicine
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prescribing followed a similar trend as non-calcium-based
phosphate binder use.
Laboratory  trends  post-initiation
Post-initiation trends in CKD-MBD biochemical markers are
described in Fig. 3 (supplementary underlying data and addi-
tional graphs are available on-line). Commensurate with the
increased pre-initiation levels described above, the observed
reduction – quantiﬁed as mean change and median per-
cent change from baseline – in serum iPTH for calcitriol-alfa
patients (−78.7 [95% CI: −90.4,−66.9] pg/mL; −19.2% [95% CI:
−22.1%,−16.4%]) was less marked than in paricalcitol (−165
[95% CI: −180,−151] pg/mL; −31.9% [95% CI: −35.4%,−29.4%])
or cinacalcet (−189 [95% CI: −210,−168] pg/mL; −30.5% [95%
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wI: −33.8%,−26.7%]) patients in the 3 months post-initiation
mean absolute achieved values of 332, 338 and 478 pg/mL,
espectively). Mean iPTH levels were largely maintained for
alcitriol-alfa and paricalcitol patients for the remaining of the
rst year; for cinacalcet patients levels continued to decline
rom 3 (478 pg/mL) to 6 months (431 pg/mL) before increasing
o levels similar to those observed at 3 months post-initiation
466 pg/mL).
Mean serum calcium levels increased in the ﬁrst 3 months
or calcitriol-alfa (+0.05 [95% CI: 0.04,0.05] mmol/L; +1.4%
95% CI: 1.2%,2.1%]) and paricalcitol (+0.07 [95% CI: 0.06,0.08]
mol/L; +2.5% [95% CI: 2.3%,3.3%]) patients and were then
aintained for the rest of the ﬁrst year. Increases in mean
alcium were higher for paricalcitol than for calcitriol-alfa
atients in the 6 months post-initiation. For cinacalcet initia-
ors, mean calcium dropped in the ﬁrst 3 months (−0.11 [95%
I: −0.12,−0.10] mmol/L; −4.7% [95% CI: −5.2%,−4.2%]) and
emained below the pre-initiation levels despite subsequent
ncreases.
Increases in mean serum phosphate in the ﬁrst 3 months
ost-initiation were observed with calcitriol-alfa (+0.05 [95%
I: 0.04,0.07] mmol/L; +3.6% [95% CI: 2.5%,5.0%]) and paricalci-
ol (+0.07 [95% CI: 0.05,0.09] mmol/L; +4.9% [95% CI: 2.7%,6.7%]).
ean phosphate decreased in cinacalcet initiators over the
ame period; the decrease was more  substantial than for cal-
ium (−0.18 [95% CI: −0.21,−0.15] mmol/L; −10.6% [95% CI:
12.3%,−9.3%]) and continued to 12 months.
atterns  of  discontinuation  and  associated  patient
haracteristics
he proportion of calcitriol-alfa (755/2259; 33.4%) and par-
calcitol (540/1689; 32.0%) patients discontinuing treatment
main discontinuation deﬁnition: >45 day prescription gap)
as higher than for cinacalcet patients (290/1245; 23.3%).The median [Q1,Q3] time to discontinuation was 4.4 [95% CI:
2.4,10.3], 5.2 [95% CI: 2.8,11.6] and 6.6 [95% CI: 3.2,13.0] months,
respectively. Superior cinacalcet persistence became apparent
after 12 months and continued for the study duration (Fig. 4).
No separation was observed between calcitriol-alfa and pari-
calcitol treatment persistence.
No age differences were apparent in discontinuing
patients’ baseline characteristics (Table 1); females were
consistently under-represented. Eastern European patients
were overrepresented amongst the calcitriol-alfa discontin-
uers whilst Iberian Peninsula patients were over-represented
amongst discontinuing paricalcitol and cinacalcet patients.
Among discontinuers, more  paricalcitol and cinacalcet
patients’ pre-dialysis systolic blood pressure was <120 mmHg
and a cancer, CVD or fracture history was more  com-
mon amongst cinacalcet patients. Haemodialysis technique
parameters also differed: dialysate calcium concentrations
were lower for paricalcitol and cinacalcet patients whilst vas-
cular catheterisation was more  prevalent.
Major biochemical differences were observed for CKD-
MBD  parameters. Whilst mean pre-discontinuation iPTH
levels were more  similar for all three therapies (296 [95%
CI: 274,319] pg/mL, 276 [95% CI: 252,301] and 313 [95% CI:
268,358] pg/mL, respectively, for calcitriol-alfa, paricalcitol and
cinacalcet), pre-discontinuation calcium and phosphate lev-
els differed substantially. Mean pre-discontinuation calcium
was higher in paricalcitol (2.33 [95% CI: 2.31,2.34] mmol/L)
than in calcitriol-alfa (2.26 [95% CI: 2.25,2.28] mmol/L) patients,
which in turn exceeded that in cinacalcet patients (2.14
[95% CI: 2.12,2.17] mmol/L). Mean pre-discontinuation phos-
phate was similarly elevated in calcitriol-alfa (1.65 [95% CI:
1.61,1.69] mmol/L) and paricalcitol (1.66 [95% CI: 1.62,1.71]
mmol/L) patients compared to cinacalcet patients (1.45 [95%
CI: 1.39,1.50] mmol/L).
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Few discontinuing calcitriol-alfa or paricalcitol patients
were prescribed paricalcitol and calcitriol-alfa, respectively,
hence multiple AVDs prescribing was rare. Phosphate binder
prescribing was markedly higher amongst paricalcitol and
cinacalcet patients, with the proportion of patients prescribed
non-calcium-based phosphate binders also higher in these
patient groups.
Laboratory  trends  post-discontinuation
Following discontinuation (main deﬁnition; Fig. 3), mean
calcium levels decreased in calcitriol-alfa (−0.06 [95% CI:
−0.07,−0.04] mmol/L; −2.2% [95% CI: −2.7%,−1.2%]) and par-
icalcitol (−0.11 [95% CI: −0.12,−0.09] mmol/L; −3.4% [95% CI:
−4.4%,−2.4%]) patients within the ﬁrst 3 months before sta-
bilising. In cinacalcet patients mean calcium levels increased
markedly initially (+0.13 [95% CI: 0.10,0.16] mmol/L; +6.0%
[95% CI: 4.4%,7.2%]) but subsequently decreased towards lev-
els comparable with calcitriol-alfa and paricalcitol patients
at 12 months. Mean phosphate patterns were similar to cal-
cium, with rapid observed decreases in calcitriol-alfa (−0.13
[95% CI: −0.17,−0.10] mmol/L; −7.6% [95% CI: −9.6%,−5.4%])
and paricalcitol (−0.16 [95% CI: −0.20,−0.12] mmol/L; −9.3%
[95% CI: −11.7%,−6.4%]) but a slight increase in cinacalcet
discontinuers (+0.10 [95% CI: 0.05,0.15] mmol/L; +6.0% [95%
CI: 2.2%,10.3%]), with relatively stable levels after 3 months
for all three treatment groups. Post-discontinuation mean
iPTH levels increased rapidly in paricalcitol (+115 [95% CI:
91,138] pg/mL; +61.2% [95% CI: 45.8%,73.5%]) and cinacalcet
(+163 [95% CI: 120,207] pg/mL; +93.0% [95% CI: 69.2%,129.6%])
patients before stabilising; the observed increase for calcitriol-
alfa patients was more  gradual (+49 [95% CI: 29,69] pg/mL;
+32.0% [95% CI: 23.8,41.2]) at 3 months and continued to 12
months.reatment discontinuation plot (main analysis deﬁnition).
Discontinuation  sensitivity  analysis
Applying the sensitivity analysis discontinuation deﬁnition,
higher levels of discontinuation were observed for all three
treatment groups (1372, 60.7%; 1096, 64.5%; and 608, 48.8%
for calcitriol-alfa, paricalcitol and cinacalcet, respectively).
The temporal persistence patterns differed markedly (Fig. 5),
with lower observed persistence for all three therapies from
6 months. Cinacalcet persistence remained higher for most
of follow-up (over 4 years), whilst lower levels of paricalcitol
persistence was observed from 2 years.
As the discontinuation ﬁndings were deﬁnition-sensitive,
trajectory analyses were repeated using the new deﬁnition
(Fig. 3). The observed patterns were similar for serum cal-
cium and phosphate, albeit with less extreme baseline values.
The serum iPTH patterns were consistently different, however,
with prolonged increases over the year.
Discussion
In this large European haemodialysis patient cohort, more
patients initiated – as evidenced by prescriptions – calcitriol-
alfa than paricalcitol, with fewest cinacalcet initiations
observed. Major geographical prescribing practice differences
were observed, reﬂecting drug reimbursement policies and the
availability/application of national and international guide-
lines. Physician and centre habits might also inﬂuence the
observed baseline differences in sHPT treatment, with sHPT
severity and serum calcium in particular dictating prescrib-
ing patterns. High PTH, phosphorus and, to a lesser extent,
calcium were drivers for cinacalcet prescription in approved
countries.
The observed PTH reductions with the AVDs might be
mediated in part by associated increases in serum calcium.
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ihe increases in serum calcium with paricalcitol accord
ith previous observational research18 but not clinical trial
ata19,20; the stricter inclusion/exclusion criteria employed
n the RCTs might explain the discrepancy. The reduction in
ll three parameters among cinacalcet initiators is consistent
ith previous research.21–24
Whilst reasonably good real-life control of serum iPTH lev-
ls was achieved in most treated patients in this study, this
as not the case for control of serum calcium and phos-
hate, which was more  often outside KDOQI target ranges (and
o some extent also outside KDIGO ranges) in AVD-treated
atients. The less favourable pre-treatment control in the
inacalcet group than in the AVDs groups was probably due
o the secondary introduction of cinacalcet in those patients
esistant to AVDs treatment. Attainment of all three mineral
etabolism targets was poor, even with treatment. This is a
ear-universal observation, reﬂecting the real-life challenges
n this regard, where correcting one parameter often repre-
ents a trade-off against control of another.
Whilst post-initiation laboratory trajectories have been
escribed previously, as outlined above, this is possibly
he ﬁrst study to describe in detail non-persistence to
HPT treatments and the evolution of laboratory parame-
ers post-discontinuation. The greater observed persistence
o cinacalcet compared to AVDs might relate to clinician
reference or the lack of a suitable alternative in patients
ncontrolled on AVDs treatment alone. Laboratory biochem-
stry post-discontinuation largely mirrored that observed for
nitiation and differed by treatment modality: whilst iPTHincreased for all three treatment groups, calcium and phos-
phate decreased for calcitriol-alfa and paricalcitol patients
and increased for cinacalcet patients. When an alternative
prescription-coverage threshold deﬁnition for discontinua-
tion was applied, non-persistence rates increased for all
three treatment groups and laboratory trajectories were more
conservative. We  hypothesise that our main deﬁnition may
represent deﬁnitive treatment drop-outs which occur infre-
quently, whilst our sensitivity deﬁnition captures treatment
adaptations which occur more  frequently.
Drug discontinuation may be patient- or physician-led and
it was impossible to determine in this study which were
patient decisions, based on drug intolerance or pill fatigue,
and which were medical decisions based on overcorrection of
PTH levels (all treatment groups), undesirable increases in cal-
cium and phosphate levels (mostly with AVDs) or undesirable
decreases in calcium levels (with cinacalcet). Discontinuation
may also be driven by laboratory goal-attainment, suggest-
ing that some clinicians do not view sHPT as a long-term
chronic disorder requiring continuous therapy. Most initial
paricalcitol prescriptions were administered intravenously,
affording a greater clinical inﬂuence on treatment deci-
sions for this group. Nevertheless, the pattern of paricalcitol
non-persistence (main deﬁnition) was no different from the
exclusively oral calcitriol-alfa group, suggesting that, for AVDs
at least, treatment discontinuation was mainly clinician-
led.
Other methodological aspects require consideration. This
study utilised data from a single private dialysis provider,
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hence ﬁndings might partially reﬂect internal policies,
limiting generalizability. We assume 100% persistence/non-
persistence when this is unlikely. Patients could contribute
to each treatment sub-population and/or be on multi-
ple therapies at once and this is not captured/reﬂected,
increasing the potential for confounding. Accordingly, these
results could be considered within the framework of
‘assessing the effect of the initial intention of a single
treatment (or its withdrawal)’. Our 45-day rule for dis-
continuation, whilst internally consistent within AROii, is
arbitrary and other time periods might have been more
appropriate (others have advocated for data-driven def-
initions based on prescription length25). Our descriptive
analytical approach, where statistical modelling was not
utilised, does not take into consideration characteristics
(observed or otherwise) which could confound the rela-
tionship between patients’ biochemistry and treatment
initiation/discontinuation and could explain, to an extent,
the clinical differences observed between the treatment
groups. Similarly, we focused on total treatment populations
when sub-group analyses might have been more  reveal-
ing. For example, the different prescribing pattern in the
Iberian Peninsula – especially with regard to cinacalcet –
might provide insights into biochemical control which could
inform healthcare decision-making by clinicians, policy mak-
ers, payers, etc., but this was beyond the scope of the
study. Finally, we reported but did not impute missing data
which may be important if, for example, less frequent iPTH
measurement is indicative of poorer clinical care which
in turn is reﬂected in poorer control of calcium and/or
phosphorus.
In conclusion, sHPT biochemistry parameters dictated
treatment initiation and discontinuation within the con-
ﬁnes of differing geographical treatment patterns. Clinicians
appear to adhere to treatment guidelines, although goal
achievement is poor. In real-life conditions, better biological
control of sHPT appears to be more  easily achievable with
cinacalcet than with AVDs, where iPTH response might be
mediated in part by serum calcium.
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